NEW YORK (GenomeWeb News) – BG Medicine said in a filing with the US Securities and Exchange Commission today that it has regained compliance with Nasdaq listing requirements.
BG disclosed a couple of weeks ago that the Listing Qualifications Department of the Nasdaq Stock Market had informed the firm that the market value of its listed securities had closed below the minimum $50 million required for continued listing for the 30 days leading up to Dec. 10. The company was given until June 10, 2013, to regain compliance with the rule.
Nasdaq told the firm on Dec. 27 that it had regained compliance because for the consecutive business days ending Dec. 24 the market value of its listed securities was $50 million or greater.
Waltham, Mass.-based BG Medicine makes the CardioScore and Galectin-3 heart failure tests.